ArticleDiscover oncology2025
High VCP/p97 expression associates with low PD-L1 TPS in oropharyngeal squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesVCP/p97 inhibition is known to upregulate PD-L1. This study investigated the correlation between PD-L1 and VCP/p97 expression in OPSCC, as well as the expression and prognostic significance of VCP/p97 in OPSCC.
methodsThe study retrospectively included 56 patients with OPSCC. Immunohistochemical staining was performed to detect VCP/p97 and PD-L1 expression. The staining intensity of VCP/p97 and PD-L1 TPS and CPS was determined. HPV status was evaluated using immunohistochemical staining against p16 and HPV PCR. In addition, iTILs were assessed.
resultsHigh VCP/p97 expression was observed in 67.9% of the tumors. A significant association was found between high VCP/p97 expression and low PD-L1 TPS (p = 0.025) and between high VCP/p97 and low iTILs (p = 0.015). No significant correlation was found between VCP/p97 and PD-L1 CPS. VCP/p97 showed no prognostic significance in OPSCC.
conclusionVCP/p97 is frequently overexpressed in OPSCC. The significant association of high VCP/p97 expression with low PD-L1 TPS and reduced iTILs could indicate that VCP/p97 inhibitor therapy may enhance the efficacy of PD-1 checkpoint inhibitor therapy in OPSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.